Beta Bionics, Inc. Q3 2026 Earnings Conference Call & Webcast - BETA BIONICS INC

Explicit Guidance:

• FY2026 Revenue: Raised to $124 million–$126 million (previously $121M–$127M); Q4 2026 expected revenue of $29M–$31M.
• FY2026 Gross Margin: Reiterated guidance of 58.5%–59.5%; Q4 expected to see mix normalization reversing Q3's unfavorable impact.
• FY2026 Pharmacy Channel: New patient starts reimbursed via pharmacy projected at 37%–39% for the full year.
• FY2026 Operating Expenses: Expected modest increase in Q4, driven primarily by higher R&D expenses for the fully closed-loop pivotal study.
• FY2026 Capex: Q4 capital expenditures expected in the low-to-mid single-digit millions to expand Mint manufacturing.
• FY2026 Cash Flow: Expectation to achieve positive free cash flow "well ahead of historical diabetes peers."
• FY2027 Revenue: Management confirms expectation to recover Q4 2026 revenue deferrals (approx. $8.5 million) and exceed prior consensus, targeting ~$190 million in total revenue.
• FY2027 Gross Margin: Mint expected to be dilutive in 2027; however, cost characteristics and design decisions project a gross margin outcome for Mint within three years that exceeds current patch pump incumbents at scale.
• FY2027 Pharmacy Mix: Mint insurance coverage expected at ~40% of lives at launch, growing to ~50% by end of 2027.

Business-Segment Outlook:

• Mint (Patch Pump): Full U.S. commercialization scheduled for Q1 2027; manufacturing line starting at near-zero capacity with a single line running four shifts, with expansion via line replication if demand outstrips supply.
• Islet (Current Pump): Q3 new patient starts grew mid-single digits sequentially; DME channel new patient starts increased, though higher-margin islet revenue declined due to distributor stocking dynamics (expected to normalize in Q4).
• 3D Intelligence: Resubmission of 510(k) expected in mid-Q4 2026; commercial launch of ILIT3D and Mint3D projected for mid-2027 (possibility of Q4 2026 clearance if FDA accepts accelerated review of resubmission).
• Type 2 Diabetes Expansion: Real-world pivotal trial enrollment completed; indication expansion for adults with Type 2 diabetes expected mid-2027 (previously "first half" corrected to "mid-year") subject to FDA clearance.
• Next-Gen Algorithm (Fully Closed-Loop): Pivotal trial initiation in U.S. for adults with Type 1 and Type 2 diabetes "in the coming weeks"; aims to remove meal announcements entirely ("forced fully closed-loop").
• Bi-Hormonal System: Drug reformulation complete; Phase IIA trials in progress with program deemed "back on track."
• Sensor Integration: Q4 2026 launch of Islet integration with Dexcom's Stelo (referred to as "Sensionics ever since 365" in transcript); future integration planned for Mint.

Market and Competitive Outlook:

• Market Demand: Anticipates "game-changing" impact from Mint; 90% of surveyed Islet users indicated a preference to switch to Mint if out-of-pocket costs were equal.
• Share Dynamics: Strategy focuses on both market expansion and share capture; expects Mint to compete with both patch pumps and tubeless pumps, potentially converting existing Islet users and attracting new patients currently not using pumps.
• Pricing/Revenue Per Patient: Anticipates Mint reimbursement to be approximately six times the monthly revenue of DME Islet patients (~$70/month) due to different reimbursement designations (Medicare Part D/Pharmacy vs. Medical).
• Manufacturing Milestones: Mint clearance received; manufacturing capacity build-out is the primary focus for 2027 to support linear ramp of 1.5 million units for the full year.

Macro / Industry Outlook:

• Regulatory Environment: FDA engagement focused on simulator validation rather than algorithm efficacy for 3D Intelligence; expects continued scrutiny on simulation data for diabetes algorithms.
• Reimbursement Structure: Mint classified as a "patch pump" (Medicare Part D/Pharmacy) rather than a medical device, simplifying the formulary and reimbursement process compared to traditional tube pumps.
• Competitive Landscape: Management views the fully closed-loop (meal-announcement-free) approach as the "most commercially viable" architecture, targeting accessibility for primary care providers and patients less able to engage with complex devices.

Strategic Initiatives:

• Manufacturing Expansion: CapEx in Q4 and 2027 focused on semi-automated and automated manufacturing lines; future project to fully automate Mint production with separate CapEx profile.
• Sales Force Expansion: Field sales organization expanded ahead of Mint launch to increase healthcare provider awareness; ramp expected to decelerate post-launch but critical for Q1 2027 readiness.
• Capital Allocation: $161 million net proceeds from September public offering allocated to Mint manufacturing CapEx and balance sheet strength.
• Product Evolution: Continued refinement of bi-hormonal system and 3D algorithm to offer clinicians choice in algorithm options (Original, Enhanced, Conservative).

Risks and Headwinds to Outlook:

• Revenue Deferral: Potential for $8.5 million revenue deferral in Q4 2026 as prospective Islet users wait for Mint (down from previous $10M estimate); magnitude of deferral and timing of catch-up in 2027 remain subject to patient awareness and provider education.
• Regulatory Timing: 3D Intelligence clearance remains uncertain; while resubmission is in mid-Q4, final clearance is not guaranteed until 2027, though Q4 2026 clearance is a "decent possibility" if FDA continues review immediately.
• Manufacturing Constraints: Initial Mint launch capacity is low (single line); reliance on line replication and yield improvement to meet demand.
• Mix Impact: Q3 gross margin was unfavorably impacted by distributor stocking of lower-margin DME supplies (infusion sets/cartridges); expected to normalize in Q4.
• Adoption Awareness: Patient awareness of Mint is currently lower than expected; relies heavily on healthcare provider education to drive conversion.

Management Tone on the Future:

• Confidence: High confidence in Mint as a "game changer" and the largest milestone to date; describes the team as "executing across the board at the highest level."
• Hedges: Repeatedly used "subject to FDA clearance" for algorithm launches; acknowledged Q4 revenue deferral as a specific risk but expressed confidence in 2027 recovery.
• Tone Shift: Transitioned from "development-focused" to "commercial ramp" mindset; optimistic about the "fun year" ahead in 2027 with a robust product portfolio.

Miscellaneous:

• Q3 Financials: Net sales of $35.5 million (+30% YoY); Gross margin 57.3% (down QoQ due to mix, up YoY); Operating expenses $46.9 million (+46% YoY); Cash, cash equivalents, and investments $374 million.
• User Feedback: Survey of 30 active users of a competitive patch pump found all rated Mint insertion as less painful.
• CEO Sentiment: CEO stated he is "personally wearing [Mint] right now and loving it."
• Correction: CEO corrected prior guidance regarding Type 2 diabetes approval timeline from "first half" to "mid-2027."